These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Prediction of the recurrence of squamous cell carcinoma of the uterine cervix by monitoring serum TA-4].
    Author: Oishi T, Maruo T, Yamasaki M, Mochizuki M.
    Journal: Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):799-806. PubMed ID: 3598275.
    Abstract:
    In this study, serum TA-4 and CEA in 21 recurrent cases were examined in relation to the pretreatment levels and recurrent lesions. The positive serum rate on recurrence was 66.7% in TA-4, 23.8% in CEA, and the mean serum level was 22.2 +/- 38.2 ng/ml in TA-4, while 4.8 +/- 9.2 ng/ml in CEA. In cases with local and intrapelvic recurrence, the positive serum rate was 61.5% in TA-4, 15.4% in CEA, and the mean serum level was 9.4 +/- 12.1 ng/ml in TA-4, and 4.3 +/- 10.2 ng/ml in CEA. In the cases in which there was distant recurrence, the serum positive rate was 75.0% in TA-4, 37.5% in CEA, and the mean serum level was 43.1 +/- 55.7 ng/ml in TA-4 and 5.7 +/- 7.7 ng/ml in CEA. In the cases whose serum pretreatment levels were positive, the positive serum rate on recurrence was 100% in TA-4 and 40.0% in CEA, while in the cases whose serum pretreatment levels were negative, the positive serum rate on recurrence was 40.0% in TA-4 and 9.1% in CEA. In 61.9% of the recurrent cases, the increase in serum TA-4 preceded the appearance of clinical signs, while the increase in serum CEA preceded it in only 19.0% of the recurrent cases. The mean leading time for tumor markers in the diagnosis of recurrence was 77.9 days in TA-4 and 60.0 days in CEA. It is therefore concluded that serum TA-4 monitoring after treatment is able to be used in predicting the recurrence of squamous cell carcinoma of the uterine cervix.
    [Abstract] [Full Text] [Related] [New Search]